ACAD:NSD-ACADIA Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.36

Change

+0.22 (+1.36)%

Market Cap

USD 2.61B

Volume

1.22M

Avg Analyst Target

USD 20.61 (+25.98%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACAD Stock Forecast & Price:
Based on the ACADIA Pharmaceuticals Inc stock forecasts from 13 analysts, the average analyst target price for ACADIA Pharmaceuticals Inc is USD 20.61 over the next 12 months. ACADIA Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of ACADIA Pharmaceuticals Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, ACADIA Pharmaceuticals Inc’s stock price was USD 16.36. ACADIA Pharmaceuticals Inc’s stock price has changed by -2.33% over the past week, +1.49% over the past month and -1.51% over the last year.

About ACADIA Pharmaceuticals Inc (ACAD:NSD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACAD

Symbol Name Weight Mer Price(Change) Market Cap
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 2.53 %

+0.09 (+0.44%)

USD0.21B
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
LABU Direxion Daily S&P Biotec.. 0.00 % 0.96 %

+0.12 (+1.74%)

USD1.02B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.27 (+0.90%)

USD0.11B
SIZ AGFiQ U.S. Market Neutral.. 0.00 % 2.82 %

N/A

USD0.88M
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.46 (+0.58%)

USD7.34B
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

+17.30 (+1.18%)

USD5.54M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

+0.36 (+2.23%)

USD5.54M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.91% 72% C- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.91% 71% C- 48% F
Trailing 12 Months  
Capital Gain -6.41% 89% B+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.41% 88% B+ 71% C-
Trailing 5 Years  
Capital Gain -56.57% 54% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.57% 53% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain 13.60% 74% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.60% 74% C 73% C
Risk Return Profile  
Volatility (Standard Deviation) 63.16% 33% F 21% F
Risk Adjusted Return 21.53% 76% C 59% F
Market Capitalization 2.61B 94% A 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 55.79 13% F 17% F
Price/Book Ratio 6.01 18% F 13% F
Price / Cash Flow Ratio -20.79 91% A- 75% C
EV/EBITDA -10.97 93% A 83% B
Management Effectiveness  
Return on Equity -40.94% 69% D+ 32% F
Return on Invested Capital -29.25% 73% C 32% F
Return on Assets -19.32% 71% C- 26% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.88 31% F 20% F
Short Percent 8.02% 26% F 19% F
Beta 0.67 74% C 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.